CDC Proposes Medical Cannabis Question for Federal Health Survey

Federal Health Surveillance Expands to Medical Cannabis

The CDC's proposal would insert a medical marijuana question into the National Health Interview Survey, the agency's flagship health monitoring tool that reaches approximately 35,000 U.S. households annually. It's a shift in federal data collection priorities, acknowledging state-legal medical cannabis programs now operating in 38 states and four territories.

The proposed question would ask respondents whether they've used cannabis for medical purposes in the past 12 months, according to the CDC's Federal Register notice published this week. The agency didn't propose tracking specific conditions treated, dosing patterns, or product types.

Data Gap Hampers Public Health Research

Federal researchers have lacked standardized national data on medical cannabis prevalence since states began legalizing therapeutic use in 1996. That's a 30-year evidence vacuum. It's complicated policy analysis and clinical guidance development across three decades of state experimentation.

The National Health Interview Survey currently tracks prescription medication use, over-the-counter drug consumption, and dietary supplement intake, but contains no cannabis-specific module. The absence of federal tracking has forced researchers to rely on fragmented state registry data, which varies widely in reporting standards and patient privacy protections. Only 24 of the 38 medical cannabis states maintain publicly accessible patient count databases. None use uniform metrics for condition categories or consumption frequency.

Timing Aligns with Rescheduling Process

The CDC proposal arrives as the Drug Enforcement Administration advances its rulemaking to reclassify cannabis from Schedule I to Schedule III under the Controlled Substances Act, a process initiated in 2024 and now in final review stages. Schedule III status would formally recognize accepted medical use, creating regulatory pressure on health agencies to establish evidence baselines.

Rescheduling has accelerated data collection planning across multiple federal health agencies. The National Institutes of Health expanded cannabis research grant funding by 340 percent in fiscal year 2026. The Food and Drug Administration opened three new investigational new drug pathways for whole-plant cannabis studies in June.

Survey Design Faces Methodological Challenges

The proposed single-question format may undercount actual medical use, since many patients in adult-use states access cannabis through recreational channels without formal medical recommendations. Twenty-four states now operate dual medical and adult-use frameworks. Preliminary state-level surveys suggest 40 to 60 percent of therapeutic users in those jurisdictions purchase through recreational retailers to avoid registry fees and employer disclosure risks.

The CDC didn't specify whether the question would distinguish between state-registered medical cardholders and self-directed therapeutic users, a methodological gap that could produce incomparable data across legal regimes. The agency's 60-day public comment period, which closes October 26, will likely surface demands for more granular condition-specific and product-type tracking.

International Precedents Show Expanded Frameworks

Canada's National Cannabis Survey, launched in 2018 following federal legalization, tracks medical versus recreational use, consumption methods, frequency, and 12 specific condition categories on a quarterly basis. The Canadian model has produced the most comprehensive national cannabis use dataset globally, enabling real-time policy adjustments and targeted public health messaging.

Uruguay's Ministry of Public Health implemented mandatory pharmacy-level reporting in 2014 that feeds into its national health surveillance system, capturing granular data on medical cannabis patients including comorbidities, concurrent prescription medications, and adverse event reports. That integration has allowed Uruguayan researchers to publish peer-reviewed studies on cannabis-opioid substitution patterns and cannabis-benzodiazepine interactions using population-level data.

For background on how federal data collection intersects with state medical cannabis programs, see the CannIntel topic hub on CDC cannabis health data collection.

Next Steps and Implementation Timeline

If finalized after the comment period, the medical cannabis question would appear in the January 2027 National Health Interview Survey cycle, with first-year data released in aggregated form by June 2028. The CDC hasn't indicated whether it'll seek Office of Management and Budget approval for expanded modules covering conditions, products, or adverse events in subsequent survey years.

The proposal doesn't address cannabis use disorder screening, a parallel data gap that advocacy groups have urged the Substance Abuse and Mental Health Services Administration to incorporate into the National Survey on Drug Use and Health. That survey currently tracks cannabis use frequency but doesn't distinguish medical from recreational consumption or assess therapeutic outcomes.

We'll be watching whether the CDC's question design allows for longitudinal tracking of individual respondents across survey years, a capability that would enable analysis of medical cannabis initiation, continuation, and discontinuation patterns at the population level. The current proposal contains no language specifying panel-study methodology. The October 26 comment deadline will signal whether the agency faces pressure to expand beyond its single-question approach.